FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549	

Washington, D.C. 20049

STATEMENT OF CHANGES

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average burden								

Check this box if no longer subject
to Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of or Section 30(h) of the Investment Company Act of 1940

IN BENEFICIAL OWNERSHIP	OMB Number:	3235-0287					
IN DEIGE 101/12 OWNEROIM	Estimated average b	Estimated average burden					
the Securities Exchange Act of 1934	hours per response:	0.5					
etmant Company Act of 1040							

Name and Address of Reporting Person* Kim Paul						2. Issuer Name and Ticker or Trading Symbol Fulgent Genetics, Inc. [FLGT]									ationship of Reporting (all applicable) Director		ng Pe	10% O	wner
(Last)	(Fi	rst) (t NETICS, INC.	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 10/26/2023									X		Officer (give title below) CFO and Tree		Other (below) asurer	specify
4399 SA	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicabl Line)											
(Street)	NTE C	A 9	1731											X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(St	ate) (2	Zip)		Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Table	I - No	on-Deriva	tive	Secu	rities	Acc	quired	, Dis	posed of	, or B	enefic	ially	Own	ed			
1. Title of Security (Instr. 3) 2. Transact Date (Month/Day			Execution Date,		ate,			s Acquired (A) o of (D) (Instr. 3, 4		and Secur Benef Owne		ities For icially (D) d Following (I) (wnership m: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership				
								Code	v	Amount	(A) or (D)	Price	Reported Transaction(s (Instr. 3 and 4		ction(s)			(Instr. 4)	
Common	Stock			10/26/2	D23 F 9,617 ⁽¹⁾ D		\$24.	025	25 204,444			D							
		Tal	ble II								osed of, convertib			•	wne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	Execu if any	eemed Ition Date, h/Day/Year)	4. Transa Code 8)		of Deriv Secu Acqu (A) o Dispo	r osed) r. 3, 4	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title Amour Securir Underl Deriva Securir 3 and 4	nt of ties ying tive ty (Instr.	Deri Sec	rice of vative urity tr. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	/ (A) (D)				Expiration Date		Amount or Number of Shares						

Explanation of Responses:

Remarks:

/s/ Paul Kim

10/30/2023

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

^{1.} The shares were withheld from the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units held by the reporting person and assumed by the Issuer on November 7, 2022, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on November 9, 2022.